CompletedNot Applicable

Role of the Pharmacist in Detection of Drug Interactions Before Antitumor Treatment Initiation

France440 participantsStarted 2020-02-11

Plain-language summary

The purpose of this observational study is to evaluate the benefits of a pharmacist integration in an oncology ambulatory center, to prevent drug related problems (in particular drug drug interactions) at antitumor treatment initiation. The hypothesis of this work is that a drug drug interaction will be observed in 30% of cancer patients and will have a major clinical impact in 1% of the cases. The primary endpoint is the prevalence of pharmacist interventions among patients who are going to receive an oral targeted therapy or cancer chemotherapy or immunotherapy

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * legal age patients * Affiliated to social security or with another insurance system * with a solid tumor * who are going to receive an antitumor treatment (chemotherapy, immunotherapy or oral targeted therapy) Exclusion Criteria: * pregnant women * minor patient

What they're measuring

Prevalence of Pharmacist intervention

Timeframe: up to 1 week from date of inclusion

Trial details

NCT IDNCT04142567

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-04-23

View on ClinicalTrials.gov More Neoplasm trials